Sorafenib Completed Phase 2 Trials for Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01715441Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors